ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Foti Receives Del Duca Award; Wake Forest To Hire 60 Faculty.

February 11, 2000

Center Bitter Over NCI’s Reacting To IOM report, Core grant Losses, Program Staff Cuts

June 30, 1989

Two New Communications Contracts Approved

October 18, 1985

In Brief: Rosenberg, Taniguchi To Share Hammer 1985 Prize; Dennis Cain Moves To DCT From DEA Grants Review

December 6, 1985

Nixon Resignation Won’t Hurt Cancer Program, Might Lead To More Money; Weinberger Stays

August 16, 1974

ET2 Meber discusses Grants Funding Issue, Says Problem Is Money

July 23, 1993